High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study | Zendy

Andrea Giustina | Zendy; Gherardo Mazziotti | Zendy; Salvatore Cannavò | Zendy; Roberto Castello | Zendy; Giorgio Arnaldi | Zendy; Giovanna Bugari | Zendy; Renato Cozzi | Zendy; Diego Ferone | Zendy; Anna Maria Formenti | Zendy; Enza Gatti | Zendy; Silvia Grottoli | Zendy; Pietro Maffei | Zendy; Filippo Maffezzoni | Zendy; M Montini | Zendy; Massimo Terzolo | Zendy; Ezio Ghigo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study

Author(s) -

Andrea Giustina,

Gherardo Mazziotti,

Salvatore Cannavò,

Roberto Castello,

Giorgio Arnaldi,

Giovanna Bugari,

Renato Cozzi,

Diego Ferone,

Anna Maria Formenti,

Enza Gatti,

Silvia Grottoli,

Pietro Maffei,

Filippo Maffezzoni,

M Montini,

Massimo Terzolo,

Ezio Ghigo

Publication year - 2017

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2017-00142

Subject(s) - acromegaly , medicine , adverse effect , gastroenterology , lanreotide , randomized controlled trial , somatostatin , endocrinology , hormone , growth hormone

Increase in drug frequency or dose is recommended for acromegaly patients with partial response to long-acting somatostatin receptor ligands (SRLs). However, the efficacy and safety data with lanreotide (LAN) Autogel (LAN-ATG) at high dose (HD) or high frequency (HF) are still scanty.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research